Oruka Therapeutics' long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in...
BUSINESS NEWS
April 27, 2026
Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts
Oruka Therapeutics' long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies analysts to predict...
1 views
0 likes
0 comments
Oruka Therapeutics' long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies analysts to predict...
Author: Fierce Biotech
Read Original Article
